Recent Advancements in the Development of Antiprotozoal Agents
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 505
Special Issue Editors
Interests: drug discovery; medicinal chemistry; anticancer; antiprotozoal; antiviral; cystic fibrosis; photoaffinity labeling; chemotherapy; leishmania; trypanosome; trypanothione; CYP51
Special Issue Information
Dear Colleagues,
Protozoa from different genera (e.g., Plasmodium, Leishmania, and Trypanosoma) cause infections that engender several prominent and grave diseases in humans. Owing to their widespread presence and major impact in developing countries, most of the infections are categorized as Neglected Tropical Diseases. However, the distribution of such diseases has dramatically changed in recent years, with many of them being reported in other parts of the world; thus, they have become a relevant global threat for human health.
On the other hand, chemotherapy has always relied on a very few and primarily old drugs, which have major limitations including low efficacy and relevant toxicity; their use so far has been justified by the lack of effective alternatives. Hence, increasing efforts have been devoted to find alternatives of the existing chemotherapy drugs in the last decade, leading to the identification of certain effective antiprotozoal agents. Additionally, recent advancements in the knowledge of parasites’ biology have allowed for the identification of previously unknown or poorly explored pathways of protozoa, thereby providing important insights to drive the development of innovative antiprotozoal agents.
This Special Issue aims to collate papers that underscore the latest findings in the search of antiprotozoal agents with various mechanisms of action and the discovery of novel biological targets, as well as elucidate the future research directions to analyze these neglected tropical diseases. We welcome submissions of both original research articles and reviews.
Dr. Francesco Saccoliti
Dr. Alessandro Giraudo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antiprotozoal
- drug discovery
- chemotherapy
- parasite
- protozoa
- mechanism of action of antiprotozoal agents
